Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients

• Published in: International journal of molecular sciences Vol. 22; no. 10; p. 5058
• Main Authors: Géczi, Dóra, Nagy, Bálint, Szilágyi, Melinda, Penyige, András, Klekner, Álmos, Jenei, Adrienn, Virga, József, Birkó, Zsuzsanna
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 11.05.2021; MDPI
• Subjects: Annotations; biomarker; Biomarkers; Blood plasma; Brain cancer; Cell cycle; Cell division; circulating miRNA; Cyclin-dependent kinases; Genes; Glioblastoma; Kinases; MicroRNAs; miRNA; NanoString; Nervous system; network analysis; Patients; Plasma; Proteins; Tumors
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22105058

(1) Background: Glioblastoma multiforme (GBM) is among the most aggressive cancers with a poor prognosis. Treatment options are limited, clinicians lack efficient prognostic and predictive markers. Circulating miRNAs—besides being important regulators of cancer development—may have potential as diagnostic biomarkers of GBM. (2) Methods: In this study, profiling of 798 human miRNAs was performed on blood plasma samples from 6 healthy individuals and 6 patients with GBM, using a NanoString nCounter Analysis System. To validate our results, five miRNAs (hsa-miR-433-3p, hsa-miR-362-3p, hsa-miR-195-5p, hsa-miR-133a-3p, and hsa-miR-29a-3p) were randomly chosen for RT-qPCR detection. (3) Results: In all, 53 miRNAs were significantly differentially expressed in plasma samples of GBM patients when data were filtered for FC 1 and FDR 0.1. Target genes of the top 39 differentially expressed miRNAs were identified, and we carried out functional annotation and pathway enrichment analysis of target genes via GO and KEGG-based tools. General and cortex-specific protein–protein interaction networks were constructed from the target genes of top miRNAs to assess their functional connections. (4) Conclusions: We demonstrated that plasma microRNA profiles are promising diagnostic and prognostic molecular biomarkers that may find an actual application in the clinical practice of GBM, although more studies are needed to validate our results.